BR0312814A - Levamisol / avermectinas ou similares em solvente de pirrolidona - Google Patents

Levamisol / avermectinas ou similares em solvente de pirrolidona

Info

Publication number
BR0312814A
BR0312814A BR0312814-8A BR0312814A BR0312814A BR 0312814 A BR0312814 A BR 0312814A BR 0312814 A BR0312814 A BR 0312814A BR 0312814 A BR0312814 A BR 0312814A
Authority
BR
Brazil
Prior art keywords
levamisol
avermectins
pyrrolidone solvent
solvent
pyrrolidone
Prior art date
Application number
BR0312814-8A
Other languages
English (en)
Other versions
BRPI0312814B1 (pt
Inventor
Robert William Lachlan Holmes
Majid Hameed Abdul Razzak
Kour Chand Jindal
Sen Nilendu
Original Assignee
Ashmont Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30768277&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0312814(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ashmont Holdings Ltd filed Critical Ashmont Holdings Ltd
Publication of BR0312814A publication Critical patent/BR0312814A/pt
Publication of BRPI0312814B1 publication Critical patent/BRPI0312814B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)

Abstract

"LEVAMISOL/AVERMECTINAS OU SIMILARES EM SOLVENTE DE PIRROLIDONA". A presente invenção refere-se a uma formulação estável, que é adequada para administração a animais. A formulação inclui pelo menos uma substância ativa, selecionada do grupo compreendendo avermectinas e milbemicina e levamisol. Ambas as ditas substâncias ativas são dissolvidas em um solvente de pirrolidona.
BRPI0312814A 2002-07-19 2003-07-21 levamisol / avermectinas ou similares em solvente de pirrolidona BRPI0312814B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ520295A NZ520295A (en) 2002-07-19 2002-07-19 Anthelmintic formulations comprising levamisole and either an avermectin or milbemycin
PCT/NZ2003/000157 WO2004009080A1 (en) 2002-07-19 2003-07-21 Levamisole, Avermectins or similar in pyrrolidone solvent

Publications (2)

Publication Number Publication Date
BR0312814A true BR0312814A (pt) 2005-04-19
BRPI0312814B1 BRPI0312814B1 (pt) 2017-06-06

Family

ID=30768277

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0312814A BRPI0312814B1 (pt) 2002-07-19 2003-07-21 levamisol / avermectinas ou similares em solvente de pirrolidona

Country Status (8)

Country Link
US (1) US20060128641A1 (pt)
EP (1) EP1551390B1 (pt)
AU (2) AU2003281472B2 (pt)
BR (1) BRPI0312814B1 (pt)
DK (1) DK1551390T3 (pt)
NZ (1) NZ520295A (pt)
SI (1) SI1551390T1 (pt)
WO (1) WO2004009080A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA82359C2 (uk) * 2003-04-03 2008-04-10 Schering Plough Ltd Композиція (варіанти) і спосіб лікування мікробних і паразитних інфекцій у великої рогатої худоби і інших тварин
EP2301557A1 (en) * 2004-09-09 2011-03-30 Warburton Technology Limited Trace elements
BRPI0611139A2 (pt) 2005-04-29 2010-08-17 Springboard Retail Networks Licensing Srl sistemas e métodos para habilitação e gerenciamento de informações de pedidos de compra em uma rede
AR056808A1 (es) * 2005-11-18 2007-10-24 Cheminova As Formulacion de aceite en agua de avermectinas
BRPI0506279B1 (pt) 2005-12-16 2018-01-09 Npa - Núcleo De Pesquisas Aplicadas Ltda Composição sinergística de antihelmínticos e endectocidas
NZ552040A (en) * 2006-12-13 2009-04-30 Bomac Research Ltd Veterinary formulation comprising an anthelmintic compound and glyceryl acetate
BRPI0819849B8 (pt) * 2007-11-26 2021-05-25 Merial Ltd sistemas de solvente para formulações pour on para combater parasitas
AU2013201461B2 (en) * 2007-11-26 2015-10-29 Boehringer Ingelheim Animal Health USA Inc. Solvent systems for pour-on formulations for combating parasites
UA108641C2 (uk) 2010-04-02 2015-05-25 Паразитицидна композиція, яка містить чотири активних агенти, та спосіб її застосування
WO2011143479A1 (en) 2010-05-12 2011-11-17 Merial Limited Injectable parasiticidal formulations of levamisole and macrocyclic lactones
AU2016201743B2 (en) * 2010-05-12 2017-10-19 Boehringer Ingelheim Animal Health USA Inc. Injectable parasiticidal formulations of levamisole and macrocyclic lactones
AR081970A1 (es) 2010-06-24 2012-10-31 Intervet Int Bv Formulacion inyectable de una lactona macrociclica y levamisol, formulacion y uso veterinario
AU2011338573B2 (en) 2010-12-07 2016-07-28 Boehringer Ingelheim Animal Health USA Inc. Topical combination formulations of macrocyclic lactones with synthetic pyrethroids
EP2723335A4 (en) * 2011-06-23 2015-01-07 Bayer New Zealand Ltd ANTIPARASITIC COMPOSITION WITH A MACROCYCLIC LACTON AND LEVAMISOL AND METHOD FOR THE TREATMENT OF PARASITIC ATTACK
NZ594610A (en) 2011-08-16 2013-03-28 Virbac New Zealand Ltd Injectable Anthelmintic Formulations cotaining levamisole and one or more macrocyclic lactones for controlling internal parasites in ruminants
US11583545B2 (en) 2018-02-08 2023-02-21 Boehringer Ingelheim Animal Health USA Inc. Parasiticidal compositions comprising eprinomectin and praziquantel, methods and uses thereof
WO2020150032A1 (en) 2019-01-16 2020-07-23 Boehringer Ingelheim Animal Health USA Inc. Topical compositions comprising a neonicotinoid and a macrocyclic lactone, methods and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426333B1 (en) * 1996-09-19 2002-07-30 Merial Spot-on formulations for combating parasites
US5773422A (en) * 1996-01-29 1998-06-30 Komer; Gene Avermectin formulation
WO1998006407A1 (en) * 1996-07-30 1998-02-19 Ashmont Holdings Limited Anthelmintic formulations
US6054140A (en) * 1997-03-21 2000-04-25 Biogenesis S.A. Long acting injectable parasiticidal composition and the process for its preparation
ATE313952T1 (de) * 1999-06-04 2006-01-15 Nufarm Ltd Stabile biozidale zusammensetzung
US6780885B1 (en) * 2000-01-14 2004-08-24 Idexx Laboratories, Inc. Formulations and methods for administration of pharmacologically or biologically active compounds
US6340672B1 (en) * 2000-02-16 2002-01-22 Phoenix Scientific, Inc. Parasiticidal formulation and a method of making this formulation

Also Published As

Publication number Publication date
US20060128641A1 (en) 2006-06-15
WO2004009080A1 (en) 2004-01-29
AU2003281472B2 (en) 2008-07-24
EP1551390A4 (en) 2008-11-05
AU2005200099A1 (en) 2005-03-17
EP1551390A1 (en) 2005-07-13
SI1551390T1 (sl) 2014-07-31
DK1551390T3 (da) 2014-04-28
BRPI0312814B1 (pt) 2017-06-06
EP1551390B1 (en) 2014-04-02
AU2003281472A1 (en) 2004-02-09
NZ520295A (en) 2005-04-29

Similar Documents

Publication Publication Date Title
BRPI0409185A (pt) formulações veterinárias anti-helmìnticas tópicas
DK1345611T3 (da) Antibiotisk/analgetisk formulering og en fremgangsmåde til fremstilling deraf
BR0107246A (pt) Agentes diazabicìclicos ativos no sistema nervoso central
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
DK1299108T3 (da) Parasiticidt præparat samt fremgangsmåde til fremstilling af dette præparat
BRPI0418098A (pt) formulações veterinárias não contendo produtos animais
DE60131703D1 (de) Orale feste pharmazeutische Zusammensetzungen zur pH-abhängig mehrphasigen Freisetzung
DE69926386D1 (de) Propofol-formulierung
BR0313060A (pt) Composições farmacêuticas aquosas de 2,6-diisopropilfenol
BRPI0416038A (pt) gel baseado em tensoativo como um veìculo injetável de liberação sustentada de droga
CL2003002277A1 (es) Composicion farmaceutica inyectable, de deposito de liberacion prolongada, que comprende un agente beneficioso disuelto o disperso en un gel constituido por un polimero bioerosionable y biocompatible; y un solvente.
EP1100522A4 (en) ADMINISTRATION OF ACTIVE AGENTS OVER THE LUNG
BRPI0412975A (pt) espuma penetrante para uso farmacêutico
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
BRPI0408925A (pt) veìculos de fase simples não-aquosos e formulações utilizando tais veìculos
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
ATE396967T1 (de) (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten
BR0012152A (pt) Sistema de microrreservatórios na base de polissiloxanos e solventes ambifìlicos
WO1999055332A8 (en) Medicinal compositions
DE60231862D1 (de) Erodierbare polymere zur injektion
DE50311778D1 (de) Mischsystem zur löslichkeitsvermittlung von pharmazeutischen wirkstoffen in polymermatrizes
ATE493121T1 (de) Perkutane resorbierbare zubereitungen
BR9812553A (pt) Formulação medicamentosa com liberação de substância ativa controlada
BR0013283A (pt) Agente farmacêutico que compreende um derivado de benzamida como ingrediente ativo
IS8430A (is) Lyf sem inniheldur (2R)-2-própýloktansýru sem virka efnisþáttinn

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: MERIAL LIMITED (GB)

Free format text: TRANSFERIDO DE: ASHMONT HOLDINGS LIMITED

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM OS ARTIGOS 8O, 11 E 13 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B25G Requested change of headquarter approved
B25A Requested transfer of rights approved
B25A Requested transfer of rights approved